Maelys  Granal Granal

Dr. Maelys Granal Granal


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
MGMaelys Granal Granal
Maelys Granal Granal
VSVictoria Sourd
Victoria Sourd
Michel BurnierMichel Burnier
Michel Burnier
JFJean Pierre Fauvel
Jean Pierre Fauvel
AGArthur Gougeon
Arthur Gougeon
Background: Over the past three decades, the prevalence of hypertension in adults has doubled worldwide, surging from 650 million to 1.3 billion cases between 1990 and 2019. Sodium reduction is a cornerstone of non-pharmacological strategies for managing hypertension. However, recent guidelines increasingly emphasize the importance of boosting potassium intake, supported by robust evidence of its cardiovascular benefits. Despite this, the precise dose-dependent effects of potassium on blood pressure (BP) remain inadequately defined. Methods: We conducted a systematic review of randomized controlled trials (RCTs) published between 2000 and 2024 to evaluate the impact of potassium supplementation alone—assessed solely via 24-h urinary potassium excretion—on BP. A dose–response meta-analysis was performed using linear, quadratic, and one-stage cubic spline regression models. Subgroup analyses were carried out based on subjects with or without hypertension. Results: Our meta-analysis included 10 RCTs, comprising 4 studies on subjects without hypertension and 6 studies on subjects with hypertension. The dose–response relationship varied according to BP status. In subjects without hypertension, potassium supplementation had a modest negative linear effect on BP. In contrast, subjects with hypertension exhibited a markedly higher reduction in BP. Specifically, a 50 mmol/day increase in urinary potassium excretion was associated with a 0.5 mmHg reduction in systolic BP (SBP) and a 0.12 mmHg reduction in diastolic BP (DBP) in subjects without hypertension, and a 5.3 mmHg reduction in SBP and a 3.62 mmHg reduction in DBP in subjects with hypertension. Conclusion: This meta-analysis highlights the dose–response relationship between potassium supplementation and BP reduction, particularly in subjects with hypertension. While the findings offer valuable insights for refining dietary guidelines, caution is warranted due to the limited number of RCTs included in the analysis.

10 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MGMaelys Granal Granal
Maelys Granal Granal
SLSLIMANI Lydia
SLIMANI Lydia
NFNans Florens
Nans Florens
FSFlorence Sens
Florence Sens
CPCaroline Pelletier
Caroline Pelletier
JFJean-Pierre Fauvel
Jean-Pierre Fauvel
There is a need for a reliable and validated method to estimate dietary potassium intake in chronic kidney disease (CKD) patients to improve prevention of cardiovascular complications. This study aimed to develop a clinical tool to estimate potassium intake using 24-h urinary potassium excretion as a surrogate of dietary potassium intake in this high-risk population. Data of 375 adult CKD-patients routinely collecting their 24-h urine were included to develop a prediction tool to estimate potassium diet. The prediction tool was built from a random sample of 80% of patients and validated on the remaining 20%. The accuracy of the prediction tool to classify potassium diet in the three classes of potassium excretion was 74%. Surprisingly, the variables related to potassium consumption were more related to clinical characteristics and renal pathology than to the potassium content of the ingested food. Artificial intelligence allowed to develop an easy-to-use tool for estimating patients’ diets in clinical practice. After external validation, this tool could be extended to all CKD-patients for a better clinical and therapeutic management for the prevention of cardiovascular complications.

17 November 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
OIOmomene Iwelomene
Omomene Iwelomene
AGArthur Gougeon
Arthur Gougeon
Michel BurnierMichel Burnier
Michel Burnier
LBLéonie Belot
Léonie Belot
VSVictoria Sourd
Victoria Sourd
MGMaelys Granal Granal
Maelys Granal Granal
Background: Hypertension (HTN) is a leading risk factor for cardiovascular disease, and dietary sodium reduction is a cornerstone strategy for blood pressure (BP) control, particularly in vulnerable populations such as individuals with chronic kidney disease (CKD), who often present with HTN. This study aims to quantify the dose–response relationship between changes in sodium intake and changes in BP, through a meta-analysis of recent randomized controlled trials (RCTs) in individuals with CKD and with or without HTN. Methods: A systematic literature search was conducted in PubMed, Cochrane Central and Embase databases to identify RCTs published since 2000 that evaluated the isolated effect of sodium intake modification on systolic and diastolic. Only trials estimating sodium intake via 24-h urinary sodium excretion were included to ensure accurate measurement of dietary intervention. A random-effects model was used to pool effect sizes, accounting for between-study heterogeneity. Linear, quadratic and cubic dose–response models were fitted and compared with identify the best-fitting relationship between sodium change and BP change. Results: The analysis included 43 RCTs with 51 distinct population groups, involving 1759 subjects. The linear model best described the dose–response relationship in subjects with CKD, with or without HTN. A reduction in sodium intake of 40 mmol/day (approximately 2.4 g of salt) was associated with a mean systolic BP/diastolic BP reduction of −4.5 mmHg (95% confidence interval −5.8, −3.1)/−2.2 mmHg (−3.0, −1.3) in patients with CKD, −2.3 mmHg (−3.0, −1.6)/−1.1 mmHg (−1.5, −0.6) in patients with HTN and −0.3 mmHg (−0.5, −0.1)/−0.1 mmHg (−0.2, −0.1) in patients without HTN. Conclusion: Reducing sodium intake has a pronounced antihypertensive effect in patients with CKD and/or HTN. Regardless of the variability in effect according to BP status, adopting a low-salt diet represents good clinical practice and should be considered a standard prescription, particularly for individuals with CKD, as it supports better BP control and helps reduce cardiovascular risk.

29 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MGMaelys Granal Granal
Maelys Granal Granal
NFNans Florens
Nans Florens
MYMilo Younes
Milo Younes
DFDenis Fouque
Denis Fouque
Laetitia KOPPELaetitia KOPPE
Laetitia KOPPE
JFJean-Pierre Fauvel
Jean-Pierre Fauvel
Background: Arterial hypertension is highly prevalent among patients with chronic kidney disease (CKD), acting both as a cause and consequence of declining kidney function, and significantly increasing cardiovascular risk. Among modifiable risk factors, diet—particularly excessive sodium intake—plays a central role in the prevention and personalized management of CKD. Methods: This study aimed to develop an innovative, digitally accessible tool to estimate sodium intake in stages 3 to 5 CKD patients, using 24-h urinary sodium excretion as the reference standard. Results: Twenty-five clinical, biological, therapeutic, and dietary variables were collected from 493 patients followed across 6 French centers. A probabilistic Tree-Augmented Naive Bayes model was used to develop the tool based on the 15 most informative variables. The model demonstrated an internal accuracy of 71%, indicating that predicted and observed sodium intake categories matched in 71% of cases. Conclusions: This AI-based prediction model offers a promising clinical tool to estimate daily sodium intake in patients with stages 3 to 5 CKD. However, external validation using independent national and international datasets is essential to establish its robustness and generalizability prior to implementation in routine clinical practice.

29 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MGMaelys Granal Granal
Maelys Granal Granal
VSVictoria Sourd
Victoria Sourd
Michel BurnierMichel Burnier
Michel Burnier
JFJean Pierre Fauvel
Jean Pierre Fauvel
AGArthur Gougeon
Arthur Gougeon
Background: The global prevalence of hypertension in adults has doubled in 30 years, rising from 650 million to 1.3 billion between 1990 and 2019. Although reducing sodium intake is one of the first core of non-pharmacological hypertension management guidelines, recent guidelines strongly emphasize the need for increased potassium intake due to accumulating evidence of its cardiovascular benefits. Methods: We conducted a systematic review to identify randomized controlled trials evaluating the effect of potassium supplementation (measured through 24-hour urinary potassium excretion) on systolic blood pressure. A dose-response meta-analysis was performed using three regression models: linear, quadratic and one-stage cubic spline. Subgroup analyses were performed according to hypertensive or normotensive status. Results: The meta-analysis included 10 randomized clinical trials comprising 4 studies in normotensive individuals and 6 in hypertensive patients. The dose-response relationship differed based on participants’ blood pressure status. Subgroup analyses revealed a weak negative linear effect of potassium on systolic blood pressure in normotensive individuals, while a stronger negative linear relationship was observed in hypertensive patients. The dose-response meta-analysis predicted that for a 50 mmol increase in urinary potassium excretion over 24 hours, systolic blood pressure decreased by 0.5 mmHg in the normotensive group and by 5.3 mmHg in the hypertensive group. Conclusion: These meta-analysis results confirm a dose-response relationship between potassium supplementation and systolic blood pressure reduction, particularly in individuals with hypertension. Predictions should be viewed with caution due to the limited number of studies included in the study. Novelty and relevance: What is new?: The dose-response relationship between change in potassium intake and change in systolic blood pressure was described using three statistical models (linear, quadratic and cubic spline) to avoid a priori assumptions. The dose-response meta-analysis revealed a weak linear relationship between increased potassium intake and decreased systolic blood pressure in normotensive individuals. The effect was more pronounced in hypertensive patients. What is relevant?: The meta-analysis specifically addresses the impact of change in potassium intake on change in systolic blood pressure selecting only recent (since the 2000s), high-quality randomized clinical trials in witch potassium intake was accurately estimated through 24-hour urinary potassium excretion. The included studies underwent rigorous assessment of bias. These analyses stratified by normotensive or hypertensive status align with current therapeutic and nutritional management practices, as well as recent diagnostic methods (measuring devices, thresholds). These findings aim to facilitate decision-making for future national and international nutritional recommendations. Clinical/pathophysiological implications?: The results of this dose-response meta-analysis support current nutritional recommendations to increase dietary potassium intake to lower blood pressure, particularly in hypertensive patients. Improved potassium intake management could significantly improve blood pressure control and reduce cardiovascular risk, particularly in high-risk hypertensive patients.